Radioimmunotherapy with 131I-L19SIP in patients with cancer

• Research type

  Research Study

• Full title

  A phase I/II dose finding and efficacy study of the tumour targeting human 131I-L19SIP monoclonal antibody in patients with cancer.

• IRAS ID

  745

• Sponsor organisation

  Philogen S.p.A.

• Eudract number

  2007-007241-12

• ISRCTN Number

  n/a

• Research summary

  L19 sip is an antibody fragment that targets tumour cells that have a particular protein associated with them. By linking L19 with a radioactive tag (131 I-L19 sip) we can deliver radiation specifically to the tumour and kill the cancer cells. A previous phase 1 trial using 131 I-L19 sip was performed using a lower dose of radiation and the drug has been shown to be safe with some promising signs of effectiveness including improvements in pain, quality of life and also in tumour scans. We therefore propose to perform further studies with higher doses of radiation to explore safety and effectiveness.

• REC name

  London - Harrow Research Ethics Committee

• REC reference

  08/H0714/77

• Date of REC Opinion

  26 Sep 2009

• REC opinion

  Favourable Opinion